USE OF CANNABIDIOL PREPARATIONS IN THE TREATMENT OF FRAGILE X SYNDROME
The present invention relates to the use of a cannabidiol (CBD) preparation in the treatment of Fragile X syndrome (FXS). In particular the CBD preparation is characterized by chemical components and/or functional properties that distinguish them from prior CBD compositions. Preferably the CBD used is in the form of a botanically derived purified CBD which comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. The other cannabinoids present are THC at a concentration of less than or equal to 0.1% (w/w); CBD-C 1 at a concentration of less than or equal to 0.15% (w/w); CBDV at a concentration of less than or equal to 0.8% (w/w); and CBD-C 4 at a concentration of less than or equal to 0.4% (w/w). The botanically derived purified CBD preferably also comprises a mixture of both trans-THC and cis-THC. Alternatively, a synthetically produced CBD is used.
1 . A method of treating Fragile X syndrome (FXS) comprising administering a cannabidiol (CBD) preparation to the subject in need thereof.
2 . The method according to claim 1 , wherein the CBD preparation comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids, wherein the less than or equal to 2% (w/w) other cannabinoids comprise the cannabinoids tetrahydrocannabinol (THC); cannabidiol-C1 (CBD-C1); cannabidivarin (CBDV); and cannabidiol-C4 (CBD-C4), and wherein the THC is present as a mixture of trans-THC and cis-THC.
3 . The method according to claim 1 , wherein the treatment of FXS is the treatment of seizures associated with FXS.
4 . The method according to claim 1 , wherein the treatment of FXS is the treatment of cognitive symptoms associated with FXS.
5 . The method according to claim 1 , wherein the treatment of FXS is the treatment of behavior associated with FXS.
6 . The method according to claim 1 , wherein the CBD is present is isolated from cannabis plant material.
7 . The method according to claim 1 , wherein at least a portion of at least one of the cannabinoids present in the CBD preparation is isolated from cannabis plant material.
8 . The method according to claim 1 , wherein the CBD is present as a synthetic preparation.
9 . The method according to claim 8 , wherein at least a portion of at least one of the cannabinoids present in the CBD preparation is prepared synthetically.
10 . The method according to claim 1 , wherein the dose of CBD is greater than 5 mg/kg/day.
11 . The method according to claim 1 , wherein the dose of CBD is 20 mg/kg/day.
12 . The method according to claim 1 , wherein the dose of CBD is 25 mg/kg/day.
13 . The method according to claim 1 , wherein the dose of CBD is 50 mg/kg/day.
14 . (canceled)